Loading
A phase 2 trial of ICP-192 in biliary tract cancer, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma is a phase 2 interventional study registered as NCT05678270 by Beijing InnoCare Pharma Tech Co., Ltd., with 70 participants planned, started 2022-11-15 and due to reach its primary completion in 2026-05. Interventions recorded: ICP-192.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares FGFR2 and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/